Pulser Inc. – Apple-Simple, Google-Smart

Mission: "Fuse the best elements of medical research and mathematical analytics to win the war on human disease and suffering."

The $70 B Problem Nobody Has Fixed
  • Clinical sponsors spend US $40–70 B yearly on trials that creep phase-by-phase.
Static Trials = Snapshot Science

Traditional Clinical Data Management (CDM) relies on one-off "snapshots," manual queries, and placebo arms that halve enrollment.

Pulser turns these snapshots into movies—creating continuous data streams.

Pulser's "Self-Driving Trial" Engine
Data Stream

Continuous multi-source collection

AI Processing

Real-time analysis

Smart Design

Dynamic trial optimization

Faster Results

Accelerated conclusions

Digitized Human Intelligence

Pulser's stack deploys Hidden Markov Models, Manifold Discovery, Topology Analytics and more.

Eight provisional patents already filed.

Flywheel of Compounding Advantages
Data Moat

Every trial enlarges a federated EMR graph.

Learning Loop

Models self-improve with each pass.

Marketplace Upside

Hospitals earn revenue, sponsors gain speed, patients get therapy.

Center caption: –70% cost | –50% time.

Business Model

Pulser aims for US $50–100M ARR within 18 months.

Market > Uber's Launch TAM
Traction & 36-Month Roadmap
2024

Sandbox trial inside single hospital ✓

2025

2–4 paid adaptive trials start; seed KPIs.

2026

Library of reusable synthetic control arms.

2027

Cash-flow break-even; platform opens to CRO partners.

Technology Architecture (Secure by Design)
In-place analytics

Data never leaves HIPAA cloud

Zero-trust security

Led by CIO Dipak Reddy

GPU-backed adaptation loop

Compliant with FDA 2019 adaptive-design guidance: https://www.fda.gov/media/120711/download

Team & Advisors
Dr. Jeff Galpin MD

Founder / CEO

PI on first US gene-therapy trial

Dr. Kirstie Bellman PhD

Chief Analytics

DARPA & Aerospace AI leader

Dr. Chris Landauer PhD

Adv. Math

150+ AI papers, DoD advisor

Ken Maranga JD

Strategy/Legal

40 yrs life-science litigation

Michael Stevens PharmD

Clinical Trials

ex-VP Virology, BMS

Dipak Reddy BS CIS

CIO

20 yrs secure health-IT

Bradley Burnam

CBO

CEO, Turn Therapeutics

Dr. Brian Athey PhD

Bio-informatics

Chair, UMich CM&B

Seed / Bridge Round – US $2-4 M (mid-point US $3.5 M)
  • 47% R&D – US $1.65 M
  • 27% Payroll – US $0.95 M
  • 20% G&A – US $0.70 M
  • 6% Sales & Mktg – US $0.20 M

Runway ≈ 15 months to three paid adaptive trials.

Scale-Up Plan – Total US $10M
  • Phase 1 (Year 1) – US $3.5M foundational operations.
  • Executive & analytics salaries, GPU hardware, patents.
  • Phase 2 (Years 2-3) – ≤ US $6.5M capacity expansion & SaaS roll-out.
Financial Projections
  • Year 1 burn ≈ US $3.2M; first revenue Q4-2025.
  • Year 2 gross US $40–100M from 20 live trials.
  • Year 3-5 target US $500M+ including SaaS & equity wins.
Competitive Heat Map

Heat map shaded teal where Pulser wins on all three dimensions.

Regulatory & Industry Tailwinds
FDA Adaptive Designs Guidance (2019)

Green-lights real-time arms

VC Investment

Poured US $6.7 B into biopharma platforms Q1-2025 (DealForma). https://dealforma.com/biopharma-therapeutics-and-platforms-venture-funding-q1-2025-review/

Hospital Revenue Opportunities

Hospitals hungry for CRO-style revenue; Pulser's virtual-campus model plugs in.

The Ask & Next Steps

Seed / Bridge: US $3.5M mid-point now → validates engine & 3 paid trials.

Series A: US $6.5M follow-on to hit 20 trials & SaaS scale.

Contact: invest@pulser.ai

"Pulser turns drug development from a marathon into a sprint."

How to use: Drop each page into PowerPoint or Google Slides; assign suggested visuals; keep primary accent #009c9f for graphs and headers.